Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Recommendation of “Buy” by Brokerages

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been given a consensus rating of “Buy” by the thirteen brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $106.20.

Several brokerages recently issued reports on MNPR. Jones Trading raised shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 10th. Barclays set a $125.00 price objective on Monopar Therapeutics and gave the company an “overweight” rating in a report on Monday, October 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Wednesday, October 8th. Chardan Capital lifted their price target on Monopar Therapeutics from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Sunday, November 9th. Finally, Piper Sandler set a $95.00 target price on shares of Monopar Therapeutics and gave the company an “overweight” rating in a report on Thursday, September 25th.

Insiders Place Their Bets

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 550,229 shares of the firm’s stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the sale, the insider directly owned 272,026 shares of the company’s stock, valued at approximately $17,303,573.86. This trade represents a 66.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

Large investors have recently modified their holdings of the business. AlphaQuest LLC raised its holdings in Monopar Therapeutics by 8.5% in the 3rd quarter. AlphaQuest LLC now owns 1,935 shares of the company’s stock valued at $158,000 after acquiring an additional 151 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Monopar Therapeutics in the third quarter valued at approximately $28,000. BNP Paribas Financial Markets lifted its stake in Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Monopar Therapeutics in the second quarter valued at $34,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares during the period. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Stock Up 4.0%

MNPR stock opened at $68.63 on Monday. Monopar Therapeutics has a 52 week low of $21.00 and a 52 week high of $105.00. The stock has a market capitalization of $458.45 million, a PE ratio of -19.95 and a beta of 1.46. The firm has a 50 day moving average of $81.44 and a 200 day moving average of $58.69.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). On average, equities research analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.